You are here: Industry Insights > Lannett

News List

Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules) prnewswire
November 05, 2020
Lannett Company, Inc. announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP).
Lannett Announces FDA Approval of NDA for Branded Anesthetic Product americanpharmaceuticalreview
January 17, 2020
Lannett Company announced the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL) ...
Lannett Enters Into Distribution Agreement with Elite Pharmaceuticals for Dantrolene americanpharmaceuticalreview
July 01, 2019
Lannett Company has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg.
Lannett Initiates Human Clinical Trial of Biosimilar Insulin Glargine americanpharmaceuticalreview
June 06, 2019
Lannett announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).
Lannett Announces Board of Directors Appointment americanpharmaceuticalreview
May 24, 2019
Lannett announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019. Following the appointment of Dr. Rewolinski, the board will comprise eight directors.
Lannett Enters Into Agreement with Amneal for Levothyroxine americanpharmaceuticalreview
November 13, 2018
Lannett Enters Into Agreement with Amneal for Levothyroxine
Lannett Receives FDA Approval for Oxycodone, Acetaminophen Tablets americanpharmaceuticacreview
September 28, 2017
Our planned product launches, combined with our on-going integration and cost reduction efforts, are just some of the factors that give us confidence Lannett's future is bright."
Lannett Receives Approval for Dexmethylphenidate Hydrochloride Tablets americanpharmaceuticacreview
September 27, 2017
Dexmethylphenidate Hydrochloride Tablets are used for the treatment of attention deficit and hyperactivity disorder (ADHD).
Lannett Receives Approval for Esomeprazole Magnesium Delayed-Release Capsules americanpharmaceuticacreview
September 06, 2017
For the 12 months ended July 2017, total U.S. sales of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg, at Average Wholesale Price (AWP) were approximately $1.4 billion, according to IMS.
Lannett Announces Approval for Levocetirizine Dihydrochloride Oral Solution americanpharmaceuticalreview
May 17, 2017
Lannett Company announced it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) ...

Previous page 1 2 Next page